Literature DB >> 16461476

Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats.

M Song1, B Xia, J Li.   

Abstract

BACKGROUND AND AIMS: Butyrate enemas have been shown to be effective in treatment of ulcerative colitis, but the mechanism of the effects of butyrate is not totally known. This study evaluates effects of topical treatment of sodium butyrate (NaB) and 5-aminosalicylic acid (5-ASA) on the expression of trefoil factor 3 (TFF3), interleukin 1beta (IL1beta), and nuclear factor kappaB (NFkappaB) in trinitrobenzene sulphonic acid (TNBS) induced colitis in rats.
METHODS: Distal colitis was induced in male Wistar rats by colonic administration of TNBS and colonically treated with NaB, 5-ASA, combination of NaB and 5-ASA, and normal saline for 14 consecutive days. Colonic damage score, tissue myeloperoxidase (MPO) activity, TFF3 mRNA expression, serum IL1beta production, and tissue NFkappaB expression were determined, respectively.
RESULTS: Treatment of NaB, 5-ASA, and the combination improved diarrhoea, colonic damage score, and MPO activities, increased TFF3 mRNA expression, and decreased serum IL1beta production and tissue NFkappaB expression. The combination therapy of NaB and 5-ASA had better effects than any other single treatment.
CONCLUSIONS: The combination of topical treatment of NaB and 5-ASA was effective for relieving and repairing colonic inflammation and the effects were related to stimulation of TFF3 mRNA expression and down-regulation of IL1beta production and NFkappaB expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461476      PMCID: PMC2596699          DOI: 10.1136/pgmj.2005.037945

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  33 in total

1.  Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition.

Authors:  J Li; G W Peet; D Balzarano; X Li; P Massa; R W Barton; K B Marcu
Journal:  J Biol Chem       Date:  2001-02-21       Impact factor: 5.157

2.  Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha.

Authors:  S Murakami; V Lefebvre; B de Crombrugghe
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

3.  Effect of sodium butyrate on reactive oxygen species generation by human neutrophils.

Authors:  Q Liu; T Shimoyama; K Suzuki; T Umeda; S Nakaji; K Sugawara
Journal:  Scand J Gastroenterol       Date:  2001-07       Impact factor: 2.423

4.  A functional NF-kappaB binding site in the human papillomavirus type 16 long control region.

Authors:  V Fontaine; E van der Meijden; J de Graaf; J ter Schegget; L Struyk
Journal:  Virology       Date:  2000-06-20       Impact factor: 3.616

5.  Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis.

Authors:  H Lührs; T Gerke; J G Müller; R Melcher; J Schauber; F Boxberge; W Scheppach; T Menzel
Journal:  Scand J Gastroenterol       Date:  2002-04       Impact factor: 2.423

6.  Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease.

Authors:  K B Hahm; Y H Im; T W Parks; S H Park; S Markowitz; H Y Jung; J Green; S J Kim
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

7.  Secretion of the trefoil factor TFF3 from the isolated vascularly perfused rat colon.

Authors:  F Moro; F Levenez; S Durual; P Plaisancié; L Thim; A S Giraud; J C Cuber
Journal:  Regul Pept       Date:  2001-09-15

8.  Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells.

Authors:  H Lührs; T Gerke; F Boxberger; K Backhaus; R Melcher; W Scheppach; T Menzel
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

9.  Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate.

Authors:  H Lührs; T Gerke; J Schauber; G Dusel; R Melcher; W Scheppach; T Menzel
Journal:  Int J Colorectal Dis       Date:  2001-08       Impact factor: 2.571

10.  Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity.

Authors:  L J Egan; D C Mays; C J Huntoon; M P Bell; M G Pike; W J Sandborn; J J Lipsky; D J McKean
Journal:  J Biol Chem       Date:  1999-09-10       Impact factor: 5.157

View more
  31 in total

1.  5-aminosalicylic acid (5-ASA) can reduce levels of oxidative DNA damage in cells of colonic mucosa with and without fecal stream.

Authors:  Caroline Caltabiano; Felipe Rodrigues Máximo; Ana Paula Pimentel Spadari; Daniel Duarte da Conceição Miranda; Marcia Milena Pivatto Serra; Marcelo Lima Ribeiro; Carlos Augusto Real Martinez
Journal:  Dig Dis Sci       Date:  2010-11-02       Impact factor: 3.199

2.  Protection of Veratrum nigrum L. var. ussuriense Nakai alkaloids against ischemia-reperfusion injury of the rat liver.

Authors:  Zhen-Zhen Wang; Wei-Jie Zhao; Xue-Song Zhang; Xiao-Feng Tian; Yu-Zhu Wang; Feng Zhang; Jin-Chan Yuan; Guo-Zhu Han; Ke-Xin Liu; Ji-Hong Yao
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

3.  Milk fat globule-epidermal growth factor 8 is decreased in intestinal epithelium of ulcerative colitis patients and thereby causes increased apoptosis and impaired wound healing.

Authors:  Qiu-jie Zhao; Yan-bo Yu; Xiu-li Zuo; Yan-yan Dong; Yan-qing Li
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Sulforaphane protects liver injury induced by intestinal ischemia reperfusion through Nrf2-ARE pathway.

Authors:  Hai-Dong Zhao; Feng Zhang; Gang Shen; Yu-Bing Li; Ying-Hua Li; Hui-Rong Jing; Ling-Fei Ma; Ji-Hong Yao; Xiao-Feng Tian
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 5.  Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Authors:  Jessica Soldavini; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2013-07-10       Impact factor: 3.199

Review 6.  A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier.

Authors:  Wangxin Liu; Xianliang Luo; Jun Tang; Qiufen Mo; Hao Zhong; Hui Zhang; Fengqin Feng
Journal:  Eur J Nutr       Date:  2020-11-12       Impact factor: 5.614

7.  Effects of recombinant human intestinal trefoil factor on trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  Jin Li; Rui Zhou; Wen-Cheng He; Bing Xia
Journal:  Mol Biol Rep       Date:  2010-12-12       Impact factor: 2.316

8.  Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis.

Authors:  Ayumi Yoshizaki; Toshiyuki Nakayama; Shinji Naito; Ichiro Sekine
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

9.  Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats.

Authors:  Hai-Qiang Zhang; Tomas T Ding; Jun-Sheng Zhao; Xin Yang; Hai-Xia Zhang; Juan-Juan Zhang; Yun-Long Cui
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

10.  Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22-dependent manner.

Authors:  Philip B Busbee; Lorenzo Menzel; Haider Rasheed Alrafas; Nicholas Dopkins; William Becker; Kathryn Miranda; Chaunbing Tang; Saurabh Chatterjee; Udai Singh; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  JCI Insight       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.